Dynavax Technologies (DVAX) Stock
Healthcare sector company. Here's the price, business snapshot, and what's worth knowing about Dynavax Technologies in October 2026.
Dynavax Technologies Corporation (DVAX) is a commercial-stage biotechnology company centred on vaccine adjuvant technology and vaccine development. Its core asset is CpG 1018, an adjuvant designed to enhance immune responses and used in approved vaccine formulations; the company also advances candidate vaccines and immuno-oncology approaches through internal programmes and partnerships. With a market capitalisation of around $1.19 billion, Dynavax generates revenues through product sales, licences and collaborations, but its financial profile can be uneven as clinical progress and partner deals evolve. Investors should note the typical biotech risks: clinical trial outcomes and regulatory decisions can be binary, competition is strong, and further capital raising may be required to fund development. This summary provides general educational information only and is not investment advice; suitability depends on individual circumstances and you should consult a professional before acting.
Dynavax Technologies (DVAX) Stock Forecast
Analyst price target, next 12 months
$24.00
+54.8% vs today's $15.50
Price range over the last 12 months
Close to its 12-month high
Analysts covering Dynavax Technologies have a consensus 12-month target of $24.00, above the current price of $15.50.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Dynavax stock with a target price of $24, indicating strong growth potential.
Financial Health
Dynavax Technologies is showing strong revenue and cash flow, with impressive profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Adjuvant Technology Edge
CpG 1018 can strengthen immune responses and enable dose-sparing, which is scientifically noteworthy — though clinical and commercial adoption is not guaranteed.
Partnerships & Sales
Dynavax works with partners and licensing deals to extend reach and revenue, but income depends on product uptake and contractual terms.
Pipeline Progress Watch
Clinical readouts and regulatory decisions can materially move the share price, offering potential upside but also significant downside risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
